Send to

Choose Destination
See comment in PubMed Commons below
Cell Biosci. 2013 Dec 6;3(1):46. doi: 10.1186/2045-3701-3-46.

Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17.

Author information

State Key Laboratory of Cancer Biology & Xijing Hospital of Digestive Disease, Xijing Hospital, Fourth Military Medical University, 127 Changle Western Road, Xi'an 710032, Shaanxi Province, China.
Department of Pediatric Dentistry, School of Stomatology, Fourth Military Medical University, Xi'an 710032, China.
Contributed equally



Accumulating evidences have identified the immunoregulatory features of stem cells. In this study, the immunoregulation of bone marrow-derived stem cells (BMSCs) transplanted into patients with HBV-related decompensated cirrhosis and mouse model of liver injury induced by carbon tetrachloride (CCl4) administration was observed.


Compared with healthy controls, patients with HBV-related decompensated cirrhosis showed significantly higher levels of TNF-alpha, IL-12, TGF-beta1, IL-17, and IL-8. However, only IL-17 was markedly decreased after autologous BMSCs transplantation during their follow-up. The same results were found in the CCl4-treated mice. Furthermore, we found that exogenous IL-17 partly abolished the therapeutic effect of BMSCs whereas IL-17-specific antibody promoted improvement of liver injury in CCl4-treated mice, resembling the therapeutic effect of BMSCs transplantation.


These data suggested that BMSCs transplantation induces a decrease of IL-17 level, which at least in part delineates the mechanisms of stem cells-mediated therapeutic benefit on liver disease.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center